Antares Pharma (AIS)

Antares Pharma, Inc. (NYSE Amex: AIS) today announced the appointment of John “Jack” Howarth as Vice President of Corporate Affairs. Mr. Howarth brings to Antares a wealth of knowledge and leadership in Corporate Affairs garnered from his more than 28 years of experience in the pharmaceutical industry.

“We are very pleased that Jack is joining Antares during this significant growth period for the Company as we focus on developing and commercializing drug/device combination products,” said Paul K. Wotton, Ph.D, President and CEO. “Jack is a seasoned public affairs executive with expertise in the investor and media relations area that we expect will complement the existing organization.”

“It’s an exciting time to be joining the Antares team,” said Mr. Howarth. “Antares has a track record of success, including the recent FDA approval of Anturol, their oxybutynin 3% gel, coupled with a diverse and late stage product pipeline with multiple technologies and a comprehensive patent portfolio, giving Antares numerous opportunities for growth and an exciting future.”

Mr. Howarth joins Antares from King Pharmaceuticals, where he served as the Vice President of Investor Relations, joining the Company through King’s acquisition of Alpharma in 2008. Prior to this role, Jack held senior leadership positions in investor and media relations at KOS Pharmaceuticals and Elan Corporation, as well as positions of increased responsibility in finance and corporate development during a career spanning almost two decades at Warner Lambert Company. Mr. Howarth received his B.S. degree in Accounting from Boston College and his M.B.A. in Finance from Seton Hall University.

About Antares Pharma

Antares Pharma focuses on self-injection pharmaceutical products and topical gel-based medicines. The Company's subcutaneous and intramuscular injection technology platforms include Vibex^™ disposable pressure-assisted auto injectors, disposable multi-use pen injectors and Vision^™ reusable needle-free injectors distributed as Tjet^® and Zomajet^® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. In the injector area, Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin^® human growth hormone (hGH) and a partnership with Ferring that includes Zomacton^® hGH. In the gel-based area, the Company's FDA approved product is Anturol^® gel, an oxybutynin ATD^™ gel for the treatment of OAB (overactive bladder) which has been licensed to Watson Pharmaceuticals, Inc. for the U.S. and Canada. Antares’ portfolio includes Elestrin^® (estradiol gel) indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and marketed in the U.S. by Jazz Pharmaceuticals. Antares Pharma has two facilities in the U.S. The Parenteral Products Division located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted auto injector and pen injector systems. The Company’s corporate offices and Pharma Division are located in Ewing, New Jersey, where pharmaceutical products are developed utilizing both the Company’s transdermal systems and drug/device combination products.